CheckMyRecalls

Breckenridge Pharmaceutical, Inc. recalls

12 recall notices naming Breckenridge Pharmaceutical, Inc. since January 2025, in United States. The most recent was published 17 Jun 2026.

Latest recalls (12)

  1. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
  2. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules USPFDACGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
  3. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
  4. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
  5. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
  6. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
  7. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
  8. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
  9. Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules USPFDACGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
  10. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
  11. Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
  12. Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesFDACGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.